Therefore, dietary therapies may be considered as an adjunct to other therapies [20,21] As the chronic inflammation that accompanies IBD is characterized by infiltration of a variety of immune cells and increased expression of a number of pro-inflammatory cytokines, including IL-6, TNF-α, IL-12, IL-23, and IFN-γ, new therapeutic approaches are mainly targeting immune pathways [40]. The gene discussed is IL23A; the disease is inflammatory bowel disease.